Biocon Introduces Affordable Diabetes and Obesity Drug in the UK

Biotechnology firm Biocon has introduced its diabetes and obesity management drug in the UK after receiving approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) earlier this year.

Liraglutide Launch in the UK

The GLP-1 peptide, Liraglutide, will be marketed under the brand names:

• Liraglutide Biocon – for diabetes management
• Biolide – for chronic weight management

This launch makes Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market.

Affordable Access to Diabetes Treatment

Biocon CEO & MD Siddharth Mittal emphasized that the launch would enhance patient access to affordable treatment and address an unmet medical need.

“We will continue our efforts to expand gLiraglutide’s reach into other European markets, the US, and select global regions,” he added.

About Liraglutide (GLP-1 Peptide)

• Glucagon-like peptide-1 (GLP-1) medications help lower blood sugar levels and aid in weight loss.
• Liraglutide is a synthetic GLP-1 analog and is administered as a once-daily injection.

Stock Market Reaction

Following the announcement, Biocon’s shares were trading 3.17% lower at ₹302.15 on the BSE.